Reduced methotrexate clearance and renal impairment in a boy with osteosarcoma and earlier undetected autosomal dominant polycystic kidney disease (ADPKD)

J Pediatr Hematol Oncol. 2010 Nov;32(8):e314-6. doi: 10.1097/MPH.0b013e3181e92af4.

Abstract

We report a 12-year-old boy with osteoblastic osteosarcoma of the right femur. He was started on chemotherapy according to the EURAMOS/COSS 1 protocol. Chemotherapy with doxorubicin/cisplatin resulted in reversible acute renal failure and methotrexate levels were repeatedly elevated. Family history suggested an autosomal dominant polycystic kidney disease. Genetic testing revealed a novel mutation c.10707_10712del (p.Val3569_3570del) in exon 36 of the PKD1 gene. Patients with autosomal dominant polycystic kidney disease may be at risk for acute renal failure during chemotherapy without signs of renal impairment. A careful family history is important to exclude risk factors for renal impairment before introducing high-dose chemotherapy.

Publication types

  • Case Reports

MeSH terms

  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / pharmacokinetics
  • Bone Neoplasms / complications*
  • Bone Neoplasms / drug therapy*
  • Child
  • Humans
  • Incidental Findings
  • Kidney / metabolism
  • Kidney / physiopathology
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / pharmacokinetics*
  • Osteosarcoma / complications*
  • Osteosarcoma / drug therapy*
  • Polycystic Kidney, Autosomal Dominant / complications*
  • Polycystic Kidney, Autosomal Dominant / metabolism
  • Polycystic Kidney, Autosomal Dominant / physiopathology

Substances

  • Antimetabolites, Antineoplastic
  • Methotrexate